9. La llegada de la inmunoterapia al  cáncer de recto localmente avanzado

Flora López López

Flora López López Oncología Médica. Hospital Universitario del Sureste (Arganda del Rey), Madrid

Palabras clave: Cáncer recto, Neoadyuvancia, Inmuterapia

Abstract

El cáncer de recto localmente avanzado (CRLA) precisa de un tratamiento multimodal (quimioterapia, radioterapia y cirugía) para mejorar el control local de la enfermedad e intentar preservar el tránsito normal. En vista de los resultados que obtiene la inmunoterapia en tumores con déficit de función en las proteínas reparadoras del DNA (dMMR-mismatch repair-deficient) en el escenario metastásico, este estudio ha investigado su papel en estadios precoces.

Locally advanced rectal cancer (LARC) requires multimodal treatment (chemotherapy, radiation and surgery) to improve local disease control and try to preserve normal transit. Because of results obtained by immunotherapy in mismatch repair-deficient (dMMR) tumour in metastatic setting, this study has investigated its role in early stages.

Recibido: 06 Abril 2023
Revisión: 11 Abril 2023
Aceptado: 05 Mayo 2023

Citas

Vol. 28 N4; págs. iv22-iv40. 2017. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C,

Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up. Annals Oncology driving innovation in oncology.

Doi: https://doi.org/10.1093/annonc/mdx224

Vol. 22 N5; págs. 702-715. 2021. Conroy T, Bosset JF, Etienne PL, Rio E, François É, MesgouezNebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy

for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre,

randomised, open-label, phase 3 trial. The Lancet Oncology.

Doi: https://doi.org/10.1016/s1470-2045(21)00079-6

Vol. 22 N1; págs. 29-42. 2021. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter

H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total

mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant

chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3

trial. Lancet Oncol.

Doi: https://doi.org/10.1016/s1470-2045(20)30555-6

Vol. 40 N23; págs. 2546-2556. 2022. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB,

Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With

Total Neoadjuvant Therapy. Journal of Clinical Oncology.

Doi: https://doi.org/10.1200/jco.22.00032

Vol. 26 N13; págs. 3271-3279. 2020. Cercek A, Dos Santos Fernandes G, Roxburgh CS,

Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch Repair-Deficient Rectal Cancer and Resistance

to Neoadjuvant Chemotherapy. Clinical Cancer Research.

Doi: https://doi.org/10.1158/1078-0432.ccr-19-3728

Vol. 383 N23; págs. 2207-2218. 2020. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt

C, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New

England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa2017699